ReviewFrontiers in medicine2014
Gastrointestinal stromal tumor - an evolving concept.
Review in Frontiers in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Gastrointestinal stromal tumor of the rectum mimicking a prostatic mass: case report.Radiology case reports · 2026Article
- Liver metastases 2 years after resection of a very-low-risk duodenal gastrointestinal stromal tumor: a case report.Surgical case reports · 2022Article
- Primary extragastrointestinal stromal tumors of the prostate: A case report and literature review.Frontiers in oncology · 2022Article
- Primary Hepatic Leiomyoma in a Healthy Middle-Aged Woman: Literature Review and Case Report.Frontiers in surgery · 2021Article
- Article
- Primary Prostatic Extra-Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate as Neoadjuvant and Adjuvant Therapy: A Case Report and Literature Review.OncoTargets and therapy · 2019Article
- Primary prostatic extragastrointestinal stromal tumor: a case report and literature review.The Journal of international medical research · 2018Review
- Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.Molecular oncology · 2018Article
- Prognostic Analysis of Duodenal Gastrointestinal Stromal Tumors.Gastroenterology research and practice · 2018Article
- A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib.Genetics in medicine : official journal of the American College of Medical Genetics · 2018Article
- Two newInternational journal of clinical and experimental pathology · 2017Article
- Pazopanib in the management of advanced soft tissue sarcomas.Therapeutics and clinical risk management · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors of the gastrointestinal tract. The discovery that these tumors, formerly thought of smooth muscle origin, are indeed better characterized by specific activating mutation in genes coding for the receptor tyrosine kinases (RTKs) CKIT and PDGFRA and that these mutations are strongly predictive for the response to targeted therapy with RTK inhibitors has made GISTs the typical example of the integration of basic molecular knowledge in the daily clinical activity. The information on the mutational status of these tumors is essential to predict (and subsequently to plan) the therapy. As resistant cases are frequently wild type, other possible oncogenic events, defining other "entities," have been discovered (e.g., succinil dehydrogenase mutation/dysregulation, insuline growth factor expression, and mutations in the RAS-RAF-MAPK pathway). The classification of disease must nowadays rely on the integration of the clinico-morphological characteristics with the molecular data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.